Digital and Biomarker-Based Monitoring for Schizophrenia-Treatment Adherence

Area of Science:

• Psychiatry
• Digital Health
• Pharmacology

Background:

• Nonadherence to antipsychotics impacts nearly half of schizophrenia patients, increasing rehospitalization and suicidality risks.
• Optimizing treatment adherence is crucial for preventing life-threatening disease relapses in schizophrenia.

Purpose of the Study:

• To review innovative strategies for improving antipsychotic treatment adherence in schizophrenia.
• To discuss challenges and future directions in adherence monitoring and intervention.

Main Methods:

• A comprehensive narrative review of 76 peer-reviewed articles from major scientific databases.
• Analysis of studies focusing on digital pills, wearable devices, biomarker monitoring, and aptamer-based technologies.

Main Results:

• Digital pills show over 95% adherence detection rates; wearables track physiological data for relapse prediction.
• Biomarker and aptamer-based systems offer precise, noninvasive monitoring of antipsychotic adherence.
• Data integration allows for customized interventions and shared decision-making.

Conclusions:

• Integrating wearable and biomarker data with AI can enhance evidence-based pharmacological decisions for schizophrenia patients.
• Collaboration among healthcare professionals and policymakers is essential to overcome barriers to implementing these technologies.